Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Cash Flow (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Cash Flow for 16 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 9.58% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.9 million through Dec 2025, up 216.25% year-over-year, with the annual reading at $24.9 million for FY2025, 216.25% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$3.4 million at Gyre Therapeutics, down from $3.8 million in the prior quarter.
  • The five-year high for Net Cash Flow was $52.7 million in Q1 2021, with the low at -$52.3 million in Q3 2022.
  • Average Net Cash Flow over 5 years is -$1.1 million, with a median of -$3.7 million recorded in 2024.
  • The sharpest move saw Net Cash Flow plummeted 372.39% in 2021, then skyrocketed 1215.43% in 2025.
  • Over 5 years, Net Cash Flow stood at -$14.8 million in 2021, then tumbled by 81.57% to -$26.9 million in 2022, then surged by 174.15% to $19.9 million in 2023, then crashed by 119.05% to -$3.8 million in 2024, then increased by 9.58% to -$3.4 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$3.4 million, $3.8 million, and $21.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.